PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 19, 2026Advanced Functional Materials1 citations

Implantable Wireless Soft Electronics Integrated With Phase‐Change Materials Enable Adaptive Multistage Drug Delivery to Brain Tumor

View Full Paper
HZHaochen ZouBYBowen YangLKLinjun Kuang

Key Points

  • The research aims to create a wireless-controlled implantable system for adaptive drug delivery in brain tumors, addressing challenges in glioblastoma treatment.
  • Developed a wireless-controlled soft implantable system using phase-change materials.
  • Implemented two-stage drug delivery of temozolomide and senolytic drugs.
  • Used eddy-current heating to clear senescent tumor cells in a mouse GBM model.
  • Achieved 60.4% greater tumor suppression compared to TMZ-only devices.
  • Demonstrated 63.6% improvement over oral gavage methods while reducing systemic toxicity.
  • Showed 73.9% higher tumor inhibition in a breast cancer model versus intravenous doxorubicin.

Abstract

ABSTRACT Implantable bioelectronics enable precise therapeutic interventions, particularly for brain disorders where local drug delivery is crucial. For glioblastoma (GBM) treatment, implantable drug delivery systems face significant challenges in achieving both mechanical compatibility and reliable wireless control. Dynamic changes in the tumor microenvironment present another major challenge, as temozolomide (TMZ) treatment triggers therapy‐induced senescence (TIS), which paradoxically accelerates tumor progression, necessitating adaptive therapeutic capabilities. Developing systems that simultaneously address material constraints while enabling dynamic therapeutic responses remains a significant technical hurdle. Here, we developed a wireless‐controlled implantable soft system utilizing phase‐change materials with distinct melting points, enabling two‐stage delivery of TMZ and senolytic drugs through eddy‐current heating to clear senescent tumor cells in postoperative GBM management. In a mouse GBM model, our system achieved 60.4% greater tumor suppression than TMZ‐only devices and demonstrated 63.6% improvement over oral gavage while reducing systemic toxicity. The system's versatility was shown in a breast cancer model with 73.9% higher tumor inhibition than intravenous doxorubicin. This work represents the first implementation of adaptive multistage release of chemotherapeutic and senolytic drugs in brain implantation‐based delivery, effectively addressing TIS‐associated problems with potential applications in other complex tumor scenarios.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Zou et al. (2026) studied this question.

synapsesocial.com/papers/69e471ef010ef96374d8e203https://doi.org/10.1002/adfm.202526178
Ask AI
Helpful
Bookmark
Share
View Full Paper